Nocion Therapeutics Inc.
- Address
- 15 Main Street Suite 247
Sponsor Overview
Specializations
Chronic Cough Disorders
Nocion Therapeutics Inc. focuses on clinical research in refractory chronic cough and unexplained chronic cough, with attention to adult patients whose symptoms persist despite standard care.
- Refractory chronic cough
- Unexplained chronic cough
- Persistent cough symptom control
The sponsor’s research activity is centered on therapeutic approaches intended to reduce cough burden and improve symptom management in a difficult-to-treat respiratory condition.
Respiratory Symptom Relief
The company’s trial portfolio reflects interest in treatments aimed at modifying cough frequency and addressing the sensory and functional impact of chronic respiratory symptoms.
- Cough frequency reduction
- Adult respiratory symptom management
- Airway-related symptom burden
This area highlights a therapeutic emphasis on improving day-to-day respiratory comfort in patients with ongoing cough that lacks a clear or reversible cause.
Inhaled Therapeutics
Nocion Therapeutics Inc. is engaged in research involving inhaled treatment delivery for cough-related disease, reflecting interest in localized respiratory administration.
- Inhalation powder
- Pulmonary drug delivery
- Respiratory-targeted therapy
The sponsor’s clinical work in this area aligns with therapeutic development for conditions affecting the upper and lower airways.
Adult Patient Population
The funded research is directed toward adults living with chronic cough, placing emphasis on symptom-focused care in a mature patient population.
- Adult medicine
- Symptom-focused respiratory care
- Quality-of-life related cough outcomes
The clinical interest lies in conditions where cough persists as a primary complaint and remains a significant therapeutic challenge.
Respiratory Drug Development
As a pharmaceutical sponsor, Nocion Therapeutics Inc. is active in the development of novel therapies for chronic cough, with its clinical research concentrated on a single respiratory indication.
- Novel cough therapeutics
- Symptom-modifying respiratory medicines
- Clinical respiratory innovation
Its research landscape is defined by a focused therapeutic interest in advancing options for patients with persistent cough disorders.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of Taplucainium Chloride Inhalation Powder in Adults with Refractory or Unexplained Chronic Cough: A Randomized, Double-Blind, Placebo-Controlled Study |  Belgium Germany Poland | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 20 sites across their trial portfolio.
Therapeutic Focus
- 1.Respiratory Tract Diseases1 trial277 other sponsors
Partnered Research Centres
20 centres- Address
- Ul. Polskiego Czerwonego Krzyza 26, 33-100 Tarnow
- Address
- Deltalaan 1, 8800 Roeselare
- Address
- ul. Powstańców Wielkopolskich 66-68, 70-111 Szczecin
- Address
- ul Gdynska 1/3, 05-200 Wołomin
- Address
- Herestraat 49, 3000 Leuven
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Nocion Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.